Facebook Pixel

Cervarix Decision Delayed

Rate This
Cervical Cancer related image

A decision about whether to approve the Cervarix vaccine for cervical cancer has been delayed by the U.S. Food and Drug Administration. An announcement about a decision had been expected Tuesday.

The drug has been approved in nearly 100 other countries, but its approval has been delayed in the United States since 2007, when the FDA requested addition data from drugmaker GlaxoSmithKline, the Associated Press reported. Cervarix blocks the two main viruses that cause cervical cancer.

Another vaccine, Gardasil, has been available in the United States since 2006.

Also on Tuesday, it was reported that a 14-year-old English girl died after receiving the Cervarix vaccine. Her death appears to have been caused by an extremely rare, severe reaction to the vaccine.

The girl became ill soon after receiving the vaccine and died in hospital a few hours later, the AP reported.

Add a Comment1 Comments

EmpowHER Guest

The Cervarix vaccine contains the ingredient aluminium hydroxide as an
"adjuvant", apparently to boost the effect of the vaccine.

This article shows that the harmful effect of aluminium hydroxide as a vaccine ingredient was already known in April 2007:


Hope this is useful.


September 29, 2009 - 4:17pm
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Add a Comment

Cervical Cancer

Get Email Updates

Related Checklists

Cervical Cancer Guide

HERWriter Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!